Teva/Lonza partnership The more interesting question is obviously, which blockbuster biologic drugs are on their portfolio. Gal, Bernstein analyst quoted in <a href='read_msg.asp?message_id=34973899'>#msg-34973899</a>, said he suspected they were primarily targeting Rituxan and Enbrel.
Market Data 
Markets 
AI
